Bumper Offer - Urjas oil Just @ Rs. 1
Metolar is a prescription drug, available for use as Tablet,Capsule,Injection,Capsule. It is primarily used for the treatment of High BP. Other than this, Metolar has some other therapeutic uses, which have been discussed ahead.
The correct dosage of Metolar depends on the patient's age, gender, and medical history. Individual symptoms and route of administration also determines the right dosage. This information has been provided in detail in the dosage section.
Common side effects of Metolar include Slow heart rate (pulse). Apart from the aforementioned side effects, Metolar can also lead to other problems, which have been listed below. Normally, these side effects of Metolar are not long lasting and go away when the treatment is finished. Consult your doctor if these side effects become worse or stay for a longer duration.
In addition, Metolar's effect is Severe during pregnancy and Mild for lactating mothers. Warnings related to Metolar's effects on the liver, heart and kidney, if any, have been listed below.
Metolar is contraindicated in people with pre-existing medical conditions like Bradycardia (Slow Heart Rate) as it can result in adverse effects. Other conditions have been mentioned below in the Metolar contraindications section.
Drug interactions for Metolar have been reported in the medical literature. A complete list of these interactions is given below.
In addition to the above precautions for Metolar, it is important to know that it is not safe while driving, and is not habit-forming.
Metolar is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
| Age Group | Dosage |
Based on research, the following side effects have been observed when Metolar is used -
Moderate
Mild
Common
Is the use of Metolar safe for pregnant women?
Metolar has many dangerous side effects in pregnant women. If you are pregnant, do not consume Metolar without medical advice.
Is the use of Metolar safe during breastfeeding?
Metolar may have very limited harmful effects for breastfeeding women.
What is the effect of Metolar on the Kidneys?
Metolar is completely safe for kidneys.
What is the effect of Metolar on the Liver?
Metolar is rarely harmful for the liver.
What is the effect of Metolar on the Heart?
Metolar is rarely harmful for the heart.
Metolar should not be taken with following medicines due to severe side effects it may cause to patients -
Moderate
If you are suffering from any of the following diseases, you should not take Metolar unless your doctor advises you to do so -
Is this Metolar habit forming or addictive?
Metolar does not cause addiction.
Is it safe to drive or operate heavy machinery when consuming?
After taking Metolar, you should not drive or work on any heavy machine, as Metolar can make you drowsy.
Is it safe?
Yes, but consume Metolar only on doctor's advice.
Is it able to treat mental disorders?
Metolar is unable to treat or cure mental disorders.
Interaction between Food and Metolar
When consumed with certain foods, Metolar may take longer to have an effect. Contact your doctor about this.
Interaction between Alcohol and Metolar
Consumption of alcohol and Metolar together may have severe effects on your health.
This medicine data has been created by -
B.Pharma, Pharmacy
7 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 847-850
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 847-850
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 847-850
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 847-850
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 847-850
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 847-850
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Lopressor (metoprolol tartrate)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 148-149